中文名 | S)-5-乙酰-N-(1-(3-(3-氯-4-氰基苯基)-1H-吡唑-1-基)丙-2-基)-1H-吡唑-3-甲酰胺 |
英文名 | (S)-5-acetyl-N-(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1H-pyrazole-3-carboxamide |
别名 | 达洛鲁胺杂质2 S)-5-乙酰-N-(1-(3-(3-氯-4-氰基苯基)-1H-吡唑-1-基)丙-2-基)-1H-吡唑-3-甲酰胺 (S)-5-乙酰-N-(1-(3-(3-氯-4-氰基苯基)-1H-吡唑-1-基)丙-2-基)-1H-吡唑-3-甲酰胺 (S)-5-乙酰基-N-(1-(3-(3-氯-3-氰基苯基)-1H-吡唑-1-基)丙烷-2-基)-1H-吡唑-3-羧酰胺 (S)-5-乙酰基-N-(1-(3-(3-氯-3-氰基苯基)-1H-吡唑-1-基)丙烷-2-基)-1H-吡唑-3-羧酰胺 |
英文别名 | ORM-15341 Ketodarolutamide ORM-15341(Ketodarolutamide) 5-Acetyl-N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-... (S)-5-acetyl-N-(1-(3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl)propan-2-yl)-1H-pyrazole-3-carboxamide (S)-3-acetyl-N-(1-(3-(3-chloro-4-cyano-phenyl)-1H-pyrazol-1-yl)propan-2-yl)-1H-pyrazole-5-carboxamide 5-Acetyl-N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]-1H-Pyrazole-3-carboxamide 1H-Pyrazole-3-carboxamide, 5-acetyl-N-[(1S)-2-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]-1-methylethyl]- |
CAS | 1297537-33-7 |
化学式 | C19H17ClN6O2 |
分子量 | 396.8303 |
密度 | 1.41±0.1 g/cm3(Predicted) |
沸点 | 714.7±60.0 °C(Predicted) |
溶解度 | DMSO : 80 mg/mL母液保存:分装冻存,避免反复冻融;-20℃,1个月;-80℃,6个月(稀释后溶液温度低保存可能会析出,尽量现用现配)细胞实验:先用DMSO溶解:再用培养基进行稀释,稀释过程建议分段进行,避免浓度变化过快导致化合物析出。若稀释过程中出现化合物析出的情况, 可采用超声的方法使其复溶。在稀释时要确保工作液中 DMSO 的终浓度尽量在0.1%以下,最高不要超过0.5%,并设置相应浓度的DMSO对照组。动物实验:先用DMSO溶解:再用水或者生理盐水等去稀释,稀释过程建议分段进行,避免浓度变化过快导致化合物析出。若稀释过程中出现化合物析出的情况, 可采用超声的方法使其复溶。可以通过添加助溶剂来帮助溶解,比如植物油、Tween80、甘油、羧甲基纤维素钠和PEG400等。具体方式请参考文献。悬浊液可用于口服和腹腔注射,不会影响产品活性。 |
酸度系数 | 8.70±0.10(Predicted) |
存储条件 | -20℃ |
产品用途 | Ketodarolutamide., also known as ORM-15341 and BAY-1896953, is a potent and full antagonist for human AR (hAR) with IC50 = 38 nM. Ketodarolutamide is a nonsteroidal antiandrogen (NSAA) and the major active metabolite of darolutamide (ODM-201, BAY-1841788), an NSAA which is used in the treatment of prostate cancer in men. Similarly to its parent compound, darolutamide acts as a highly selective, high-affinity, competitive silent antagonist of the androgen receptor (AR). Both agents show much higher affinity and more potent inhibition of the AR relative to the other NSAAs enzalutamide and apalutamide, although they also possess much shorter and comparatively less favorable elimination half-lives. |
上游原料 | 2-氯-4-(4,4,5,5-四甲基-1,3,2-二噁硼烷-2-基)苯甲腈 (S)-4-(1-(2-氨基丙基)-1H-吡唑-3-基)-2-氯苯甲腈 异丙醇 |
参考资料 展开查看 | 1: Saini NK, Gabani BB, Todmal U, Sulochana SP, Kiran V, Zainuddin M, Balaji N, Polina SB, Srinivas NR, Mullangi R. Pharmacokinetics of Darolutamide in Mouse - Assessment of the Disposition of the Diastereomers, Key Active Metabolite and Interconversion Phenomenon: Implications to Cancer Patients. Drug Metab Lett. 2020 May 20. doi: 10.2174/1872312814666200521091236. Epub ahead of print. PMID: 32436836. 2: Zakkula A, Kiran V, Todmal U, Sulochana SP, Mullangi R. RP-HPLC-UV Method for Simultaneous Quantification of Second Generation Non-Steroidal Antiandrogens Along with their Active Metabolites in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg). 2019 Oct;69(10):537-544. doi: 10.1055/a-0790-8309. Epub 2018 Dec 10. PMID: 30536259. 3: Sulochana SP, Saini NK, Daram P, Polina SB, Mullangi R. Validation of an LC- MS/MS method for simultaneous quantitation of enzalutamide, N-desmethylenzalutamide, apalutamide, darolutamide and ORM-15341 in mice plasma and its application to a mice pharmacokinetic study. J Pharm Biomed Anal. 2018 Jul 15;156:170-180. doi: 10.1016/j.jpba.2018.04.038. Epub 2018 Apr 24. PMID: 29709784. 4: Balaji N, Sulochana SP, Saini NK, A SK, Mullangi R. Validated Chiral LC-ESI- MS/MS Method for the Simultaneous Quantification of Darolutamide Diastereomers and Its Active Metabolite in Mice Plasma: Application to a Pharmacokinetic Study. Drug Res (Stuttg). 2018 Nov;68(11):615-624. doi: 10.1055/a-0580-7218. Epub 2018 Mar 20. PMID: 29558780. 5: Dittakavi S, Nagas |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.52 ml | 12.6 ml | 25.2 ml |
5 mM | 0.504 ml | 2.52 ml | 5.04 ml |
10 mM | 0.252 ml | 1.26 ml | 2.52 ml |
5 mM | 0.05 ml | 0.252 ml | 0.504 ml |
微信搜索化工百科或扫描下方二维码,添加化工百科小程序,随时随地查信息!